Functional Ryanodine Receptors in the Plasma Membrane of RINm5F Pancreatic β-Cells

Christian Rosker, Gargi Meur, Emily J. A. Taylor, and Colin W. Taylor

From the Department of Pharmacology, University of Cambridge, Cambridge CB2 1PD, United Kingdom

Ryandine receptors (RyR) and inositol 1,4,5-trisphosphate receptors (IP₃R) (1, 2) are the archetypal intracellular Ca²⁺ channels. Both are widely expressed, although RyR are more restricted in their expression than IP₃R (3, 4).

In RINm5F cells, the channels were blocked by cytosolic, redenethemium. Subcellular fractionation showed that type 3 IP₃ receptors (IP₃R3) were expressed predominantly in endoplasmic reticulum, whereas RyR2 were present also in plasma membrane fractions. Using RNAi selectively to reduce expression of RyR1, RyR2, or IP₃R3, we showed that RyR2 mediates both the Ca²⁺ entry and the plasma membrane currents evoked by agonists of RyR. We conclude that small numbers of RyR2 are selectively expressed in the plasma membrane of RINm5F pancreatic β-cells, where they mediate Ca²⁺ entry.

Ryandine receptors (RyR) and inositol 1,4,5-trisphosphate receptors (IP₃R) (1, 2) are the archetypal intracellular Ca²⁺ channels. Both are widely expressed, although RyR are more restricted in their expression than IP₃R (3, 4). In common with many cells, pancreatic β-cells and insulin-secreting cell lines express both IP₃,R (predominantly IP₃R3) (5, 6) and RyR (predominantly RyR2) (7). Both RyR and IP₃,R are expressed mostly within membranes of the endoplasmic (ER), where they mediate release of Ca²⁺. Functional RyR are also expressed in the secretory vesicles (8, 9) or, and perhaps more likely, in the endosomes of β-cells (10). Despite earlier suggestions (11), IP₃,R are probably not present in the secretory vesicles of β-cells (8, 12, 13).

All three subtypes of IP₃,R are stimulated by IP₃ with Ca²⁺ (1), and the three subtypes of RyR are each directly regulated by Ca²⁺. However, RyR differ in whether their most important physiological stimulus is depolarization of the plasma membrane (RyR1), Ca²⁺ (RyR2) or additional intracellular messengers like cyclic ADP-ribose. The latter stimulates both Ca²⁺ release and insulin secretion in β-cells (8, 14). The activities of both families of intracellular Ca²⁺ channels are also modulated by many additional signals that act directly or via phosphorylation (15, 16). Although they commonly mediate release of Ca²⁺ from the ER, both IP₃,R and RyR select rather poorly between Ca²⁺ and other cations (permeability ratio, P₉/P₅ < 7) (1, 17). This may allow electrogenic Ca²⁺ release from the ER to be rapidly compensated by uptake of K⁺ (18), and where RyR or IP₃,R are expressed in other membranes it may allow them to affect membrane potential.

Both Ca²⁺ entry and release of Ca²⁺ from intracellular stores contribute to the oscillatory increases in cytosolic Ca²⁺ concentration ([Ca²⁺]ᵢ) that stimulate exocytosis of insulin-containing vesicles in pancreatic β-cells (7). Glucose rapidly equilibrates across the plasma membrane (PM) of β-cells and its oxidative metabolism by mitochondria increases the cytosolic ATP/ADP ratio, causing Kᵦₜₚ channels to close (19). This allows an unidentified leak current to depolarize the PM (20) and activate voltage-gated Ca²⁺ channels, predominantly L-type Ca²⁺ channels (21). The resulting Ca²⁺ entry is amplified by Ca²⁺-induced Ca²⁺ release from intracellular stores (7), triggering exocytotic release of insulin-containing dense-core vesicles (22). The importance of this sequence is clear from the widespread use of sulfonlurea drugs, which close Kᵦₜₚ channels, in the treatment of type 2 diabetes. Ca²⁺ uptake by mitochondria beneath the PM further stimulates ATP production, amplifying the initial response to glucose and perhaps thereby contributing to the sustained phase of insulin release (23). However, neither the increase in [Ca²⁺]ᵢ, nor the insulin release evoked by glucose or other nutrients is entirely dependent on Ca²⁺ entry (7, 24) or closure of Kᵦₜₚ channels (25). This suggests that glucose metabolism may also more directly activate RyR (7, 26) and/or IP₃,R (27) to cause release of Ca²⁺ from intracellular stores. A change in the ATP/ADP ratio is one means whereby nutrient metabolism may be linked to opening of intracellular Ca²⁺ channels because both RyR (28) and IP₃,R (1) are stimulated by ATP.

The other major physiological regulators of insulin release are the incretins: glucagon-like peptide-1 and glucose-dependent insulinotropic hormone (29). These hormones, released by
cells in the small intestine, stimulate synthesis of cAMP in β-cells and thereby potentiate glucose-evoked insulin release (30). These pathways are also targets of drugs used successfully to treat type 2 diabetes (29). The responses of β-cells to cAMP involve both cAMP-dependent protein kinase and eps (exchange factors activated by cAMP) (31, 32). The effects of the latter are, at least partly, due to release of Ca$^{2+}$ from intracellular stores via RyR (33–35) and perhaps also via IP$_3$R (36). The interplays between Ca$^{2+}$ and cAMP signaling generate oscillatory changes in the concentrations of both messengers (37). RyR and IP$_3$R are thus implicated in mediating responses to each of the major physiological regulators of insulin secretion: glucose and incretins.

Here we report that in addition to expression in intracellular stores, which probably include both the ER and secretory vesicles and/or endosomes, functional RyR2 are also expressed in small numbers in the PM of RINm5F insulinoma cells and rat pancreatic β-cells.

**EXPERIMENTAL PROCEDURES**

**Cell Culture**—RINm5F cells were cultured at 37 °C in humidified air containing 5% CO$_2$ in RPMI 1640 medium containing l-glutamine (2 mM), fetal calf serum (10%), and 2-mercaptoethanol (50 μM). Cells were passaged every 3–4 days when confluent.

**Isolation of Rat Pancreatic β-Cells**—Pancreatic β-cells were isolated from 3-week-old, male Wistar rats by Dr. Noel Smith (Department of Clinical Biochemistry) (38). Briefly, the pancreas was perfused with Hank’s balanced salt solution (HBSS, Sigma) containing collagenase P (1 mg/ml, Roche), excised and incubated at 37 °C for 15 min. The islets were then washed in cold HBSS (600 × g, 5 min) and purified using a Histopaque discontinuous gradient (Histopaque, 1.077 g/ml; Histopaque 1, 1.119 g/ml; Sigma). Dispersed cells were resuspended in RPMI medium and allowed to attach to poly-d-ornithine-coated Petri dishes for patch-clamp recordings from isolated cells.

**Subcellular Fractionation**—Confluent cells (1.2 × 10$^6$ cells) were washed twice with ice-cold phosphate-buffered saline (PBS: 136.9 mM NaCl, 2.7 mM KCl, 1.5 mM KH$_2$PO$_4$, 7.7 mM Na$_2$HPO$_4$, pH 7.4), scraped into 5 ml of the same medium, centrifuged (650 × g, 5 min) and resuspended in 850 μl of 0.3 M sucrose supplemented with Hepes (10 mM, pH 7.4), benzamidine (1 mM), NaN$_3$ (2 mM), protease inhibitors (1 Roche Applied Science complete protease inhibitor mini-tablet/10 ml) and dithiothreitol (5 mM). After homogenization (15 strokes in a Dounce homogenizer) and then passage through a 25-gauge needle (30 times), the homogenate was centrifuged (1000 × g, 10 min, to give pellet (P1) and supernatant (S1) fractions). The supernatant was then re-centrifuged (12,000 × g, 10 min, to give P2 and S2). Sucrose media were prepared in 100 mM KCl, 5 mM MgCl$_2$, 100 mM imidazole, pH 6.8. Layers of 8.5% (1 ml), 40% (1.5 ml) and 60% (1.5 ml) sucrose were successively layered beneath 750 μl of the S2 supernatant fraction. The gradient was centrifuged (100,000 × g, 2 h, Beckman Coulter SW55T rotor), and fractions (0.25 ml, 1–19) were collected from the top of the gradient.

**RNAi-mediated Knockdown of RyR1, RyR2, and IP$_3$R**—Cells (5 × 10$^5$ cells/well) grown in 6-well plates for 2 days were transfected using Lipofectamine RNAimax with a mixture of two RNAi for either RyR1, RyR2 (10 nM each, Invitrogen), or IP$_3$R (10 nM, Qiagen). After 36–48 h, cells were re-seeded (5 × 10$^5$ cells/well) and after a further 48 h transfected again with the same RNAi mixture. Cells were used 48–60 h after the second transfection. The RNAi used are listed in supplemental Table S1.

**Immunoblotting and Protein Assays**—Cells (3 × 35-mm dishes) were washed twice in PBS and lysed (PBS with 1% Triton X-100). Protein concentrations were measured using the Quant-iT protein assay kit (Invitrogen). After SDS-PAGE (3–8%, Invitrogen NuPAGE), proteins were transferred to a polyvinylidene difluoride membrane using an iBLOT apparatus (Invitrogen) and incubated with primary antibody. The antibodies used were: monoclonal IP$_3$R3 (Transduction Laboratories, 1:1000), RyR2 (Calbiochem, 1:1000), rabbit RyR1 (39) (1:1000), plasma membrane Ca$^{2+}$-ATPase (Alexis, 1:1000) and rabbit polyclonal calnexin (Santa Cruz Biotechnology, 1:500). The blots were then incubated with horseradish peroxidase-conjugated donkey anti-rabbit (AbCam, 1:5000) or goat anti-mouse (Promega, 1:5000) secondary antisera and visualized with SuperSignal West Pico chemiluminescent substrate (Pierce). Bands were quantified using GeneTools software (Syngene).

**Quantitative PCR**—Total RNA was isolated from cell lysates and reverse transcribed into cDNA (20 μl) using a fast lane cDNA direct kit (Qiagen). QPCR was performed on a RotorGene 6000 (Corbett Research) in a final volume of 15 μl using Sensimix Plus SYBR master mix (Quantace), 0.5 μM actin primer or Quantitect primers for IP$_3$R1–3 and RyR1–3, and 0.4 μl cDNA. Primers are listed in supplemental Table S2. QPCR conditions were: initial denaturation at 95 °C for 10 min, followed by 40 cycles at 95 °C for 10 s and 60 °C for 30 s. After the last cycle, a melting curve was performed to confirm the identity of the amplified product. Data were analyzed using quantification software supplied with Rotorgene 6000 (40).

**Single Channel Recording**—Cells attached to uncoated plastic Petri dishes were rinsed with, and then incubated in, bath solution (BS) containing 140 mM cesium methanesulfonate, 10 mM Hepes, 500 μM BAPTA, 270 μM CaCl$_2$ (free [Ca$^{2+}$] = 246 nM), pH 7.1. Where indicated, cesium methanesulfonate was iso-osmotically replaced by KCl, NaCl, Tris-HCl or N-methyl-$d$-glucamine-HCl. Pipettes were pulled from borosilicate glass and had resistances of 10–30 MΩ when filled with pipette solution (PS). Most recordings were performed with symmetrical solutions. Currents were recorded with an Axopatch 200B amplifier using pClamp 9.0, digitized at 10 kHz and filtered at 1 kHz. Capacitative currents were cancelled before recording. Single channel currents were recorded in the cell-attached or inside-out configuration of the patch-clamp technique. All recordings were performed at room temperature. Currents were analyzed using pClamp 9.0 software.

**Measurements of [Ca$^{2+}$]$_i$ and Mn$^{2+}$ Entry**—Cells cultured on 22-mm round glass coverslips were incubated with Fura 2AM (2 μM prepared in anhydrous DMSO) in HBSS supplemented with probenecid (2.5 mM) and Pluronic F127 (0.02%) for 45 min at 20 °C, followed by a further 45-min incubation to allow de-esterification of the indicator. HBS had the following

---

**Plasma Membrane Ryanodine Receptors**

---

**JOURNAL OF BIOLOGICAL CHEMISTRY**
rate was again measured after stimulation (Q2). The duration of the exposure to MnCl₂ (100 s) was chosen to ensure that rates of Fura 2 quenching were linear during both assay periods. The effects of stimuli on rates of Mn²⁺ entry are reported as a Q2/Q1 ratio, with the ratio uniquely determined for each single cell (see Fig. 1E).

Materials—Fura 2AM and all culture media, except serum (Sigma), were from Invitrogen. All other reagents, including Ryanodine, caffeine, 4CmC, and ruthenium red, were from Sigma.

RESULTS AND DISCUSSION

Ca²⁺ Entry Evoked by Agonists of RyR—In single cell measurements of [Ca²⁺], in RINm5F insulinoma cells, most cells responded to caffeine (1 mM) or 4chloro-2-m-cresol (4CmC, 1 mM) with a substantial increase in [Ca²⁺] (Fig. 1A and B). A lower concentration of 4CmC (0.5 mM), sufficient to activate RyR1 and RyR2, but not RyR3 (41), evoked a similar sustained Ca²⁺ signal (Δ[Ca²⁺], 275 ± 18 and 176 ± 11 nM, for 1 mM and 0.5 mM 4CmC, respectively). Treatment with a high, inactivating concentration of Ryanodine (400 μM) evoked no Ca²⁺ signal itself, but abolished the subsequent response to 4CmC (Fig. 1A). Although each stimulus was effective in the absence of extracellular Ca²⁺, both the peak amplitude and sustained responses were substantially attenuated in Ca²⁺-free medium (Fig. 1, A–D).

Pretreatment of cells in Ca²⁺-free medium with Thapsigargin (1 μM, 2 min) to empty the intracellular Ca²⁺ stores that express the SR/ER Ca²⁺-ATPase (SERCA) massively reduced the 4CmC-evoked increase in [Ca²⁺], but without abolishing it (Fig. 1C). The small residual Ca²⁺ release is probably mediated by RyR in either secretory vesicles (8, 9) or endosomes (10), both of which can accumulate Ca²⁺ by mechanisms that do not require SERCA (8, 9). Quenching of fura 2 fluorescence evoked by unidirectional Mn²⁺ entry across the PM was also stimulated by 4CmC (Fig. 1E). These results establish that in RINm5F cells, agonists of RyR stimulate both release of intracellular Ca²⁺ stores (from both ER and secretory vesicles or endosomes) and Ca²⁺ entry. Others have also reported that agonists of RyR evoke Ca²⁺ release and Ca²⁺ entry in both β-cells and insulinoma cells (20, 42).

**Figure 1.** Ca²⁺ entry evoked by agonists of RyR. A, Ca²⁺ signals evoked by 4CmC (1 mM) in HBS with or without extracellular Ca²⁺ and after pretreatment with Ryanodine (400 μM, 30 min). Traces (here and in subsequent panels) show the responses from ~50 individual cells taken from at least three independent experiments (means ± S.E., but with many error bars smaller than the symbols). B, responses to caffeine (1 mM) in normal HBS. C, Ca²⁺ signals evoked by 4CmC (1 mM) in Ca²⁺-free medium alone or after pretreatment with thapsigargin (TG, 1 μM), D, peak (after ~30 s) and sustained (after 200 s) changes in [Ca²⁺], evoked by 4CmC in the absence (open bars) and presence of extracellular Ca²⁺, and the latter after pretreatment (2 min) with nifedipine (Nf, 10 μM) or thapsigargin (1 μM). E, Mn²⁺ entry (0.5 mM) was measured by quenching of Fura 2 fluorescence in control cells (Q1). Mn²⁺ was then removed and the cells incubated with thapsigargin (1 μM) for 5 min (during the break between the traces) before again measuring Mn²⁺ entry (Q2) in the presence of thapsigargin alone (black) or with 4CmC (1 mM, red). Typical traces are shown. Summary data show the slope of the fluorescence change during the second addition of Mn²⁺ (Q2, with the stimulus) as a % (Q2/Q1) of the slope recorded during the first addition (Q1, without stimulus). Results are means ± S.E., n = 30–61. F, restoration of extracellular Ca²⁺ (1.5 mM) to cells pretreated with thapsigargin (1 μM) in Ca²⁺-free HBS fails to evoke Ca²⁺ entry.

Composition: 135 mM NaCl, 5.9 mM KCl, 1.2 mM MgCl₂, 11.6 mM HEPES, 11.5 mM glucose, and 1.5 mM CaCl₂ (replaced by 1 mM EGTA in Ca²⁺-free HBS), pH 7.3. Fluorescence ratios (excitation at 340 and 380 nm; emission at 510 nm) from single cells were collected at 20 °C at 5-s intervals. After correction for autofluorescence (by addition of 1 μM ionomycin with 10 mM MnCl₂), fluorescence ratios were calibrated to [Ca²⁺] using a look-up table created from standard Ca²⁺ solutions (Molecular Probes).

Quenching of fura 2 fluorescence by Mn²⁺ entry was measured in similarly loaded cells bathed in Ca²⁺-free HBS supplemented with 0.5 mM MnCl₂ and with fluorescence recorded after excitation at 360 nm. For all experiments, a basal rate of quench (Q1) was measured before stimulation, and the
In most cells, emptying of intracellular Ca\(^{2+}\) stores evokes store-operated Ca\(^{2+}\) entry (SOCE) across the PM, although SOCE is perhaps less widely expressed in electrically excitable cells (43). Thapsigargin (1 \(\mu\)M) did not cause a substantial increase in [Ca\(^{2+}\)\(_{i}\)], but it clearly emptied intracellular stores because it almost abolished the Ca\(^{2+}\) release evoked by 4CmC (Fig. 1C). However, thapsigargin caused no detectable Ca\(^{2+}\) entry. The small responses to thapsigargin were similar in the presence and absence of extracellular Ca\(^{2+}\) (not shown), and restoration of extracellular Ca\(^{2+}\) to thapsigargin-treated cells failed to evoke a Ca\(^{2+}\) signal (Fig. 1F). Under similar conditions, the same stocks of thapsigargin stimulated both Ca\(^{2+}\) release and SOCE in HEK cells (not shown). Furthermore, prior-treatment of RINm5F cells with thapsigargin neither evoked unidirectional Mn\(^{2+}\) entry nor affected the Mn\(^{2+}\) entry evoked by 4CmC (Fig. 1E). We conclude that depletion of intracellular Ca\(^{2+}\) stores fails to evoke significant SOCE in RINm5F cells. The lack of detectable SOCE is consistent with reports from insulinoma (44) and \(\beta\)-cells (20, 27, 45–47) where SOCE was either very small or undetectable.

Although agonists of RyR evoke Ca\(^{2+}\) release (Fig. 1, B and C) and SOCE is apparently absent from RINm5F cells (Fig. 1, E and F), both the initial and sustained responses to caffeine (not shown) or 4CmC (Fig. 1D) were substantially reduced in the absence of extracellular Ca\(^{2+}\). Blocking voltage-gated L-type Ca\(^{2+}\) channels with nifedipine (10 \(\mu\)M) had no significant effect on either the peak or sustained responses to 4CmC, and nor had thapsigargin any effect on the sustained Ca\(^{2+}\) signals evoked by 4CmC (Fig. 1D).

Depolarization with 25 nM KCl (by replacement of NaCl) caused an increase in [Ca\(^{2+}\)\(_{i}\)], (by 291 ± 12 nM, \(n = 48\)) that was substantially blocked (~60%) by 10 \(\mu\)M nifedipine (not shown). Under these depolarizing conditions and with nifedipine (10 \(\mu\)M) present, 4CmC (1 mM) evoked a further increase in [Ca\(^{2+}\)\(_{i}\)], of 169 ± 21 nM (\(n = 46\)). The latter suggests that although 4CmC may lead to some activation of L-type Ca\(^{2+}\) channels (note the small, but statistically insignificant, inhibition of the peak 4CmC-evoked Ca\(^{2+}\) signal by nifedipine in Fig. 1D), these channels can mediate no more than a very small component of the 4CmC-evoked Ca\(^{2+}\) signal.

The results so far establish that agonists of RyR evoke Ca\(^{2+}\) (or Mn\(^{2+}\)) entry that is independent of SOCE or voltage-gated Ca\(^{2+}\) channels. Another study also showed that a RyR-selective agonist stimulates Ca\(^{2+}\) entry via a SOCE-independent pathway in \(\beta\)-cells, although it speculated that it resulted from RyR-mediated release of Ca\(^{2+}\) from a non-ER store causing activation of Ca\(^{2+}\)-permeable TRP (transient receptor potential) channels in the PM (20). Our subsequent experiments show that the Ca\(^{2+}\) entry is mediated directly by RyR in the PM.

**Differential Distributions of RyR and IP\(_{3}\)R**—The quantitative PCR (QPCR) analysis shown in supplemental Table S3 and the immunoblot shown in Fig. 2A, establish that RyR2 and IP\(_{3}\)R3 are the major intracellular Ca\(^{2+}\) channels in RINm5F cells. These results are consistent with previous reports demonstrating that IP\(_{3}\)R3 (5, 14, 48) and RyR2 (7, 9, 14, 33, 49) are the major subtypes of intracellular Ca\(^{2+}\) channels in pancreatic \(\beta\)-cells (5, 14, 33, 48, 49) and RINm5F cells (5, 6, 14, 48). Our results are also consistent with evidence showing low-level expression of RyR1 (9, 14, 33) and with the lack of evidence that \(\beta\)-cells or insulinoma cells express RyR3 (9).

IP\(_{3}\)R3 and RyR2 were similarly distributed between the supernatant and pellet fractions after crude fractionation (Fig. 2B). Although these simple analyses failed to separate PM and ER membranes, the results are consistent with the substantial presence of IP\(_{3}\)R3 and RyR2 within intracellular Ca\(^{2+}\) stores.

**FIGURE 2. Expression of RyR2 in RINm5F cells.** A, Western blots (60 \(\mu\)g protein/lane) from RINm5F cells stained with the indicated antibodies (typical of at least 3 blots). B, homogenate of RINm5F cells (see “Experimental Procedures”) was subjected to two centrifugation steps (as shown) and from each supernatant (S) and pellet (P), material equivalent to the same number of cells was analyzed by Western blotting. The distribution of each protein within the supernatant fraction is shown beneath each gel (mean ± S.E., \(n = 3\)). The low level of expression of RyR1 (supplemental Table S3) prevented reliable quantification of its distribution after the first centrifugation step. The S2 supernatant was further analyzed on a discontinuous sucrose gradient, and fractions (0.25 ml, 1–19) were analyzed by Western blotting. A typical blot is shown. C, The distribution of proteins between fractions (means ± S.E., \(n = 3–6\)) is shown as a percentage of that detected in fractions 6–15 (none of the proteins were detected in the other fractions).
However, sucrose-gradient centrifugation of a fraction (S2 in Fig. 2B) that included 20% of all IP₃R3 and RyR2, clearly separated PM from ER, and IP₃R3 from RyR2. IP₃R3 appeared in the same fractions as calnexin, an integral ER protein, whereas RyR2 was concentrated in the same fractions as the plasma membrane Ca²⁺-ATPase (PMCA, Fig. 2, B and C). These results do not prove that RyR2 are expressed in the PM, but they strongly suggest that at least some RyR2 are expressed in a different membrane compartment to IP₃R3.

Plasma Membrane Channels Activated by Agonists of RyR—In cell-attached patch-clamp recordings from RINm5F cells with cesium methansulphonate in both the bathing solution (BS) and pipette solution (PS), concentrations of 4CmC (1 mM) or caffeine (1 mM) typical of those used to activate RyR (41) stimulated channel activity (Fig. 3A). Pre-incubation (30 min) with a high concentration (400 μM) of ryanodine, sufficient to inhibit all RyR subtypes (50), abolished responses to both stimuli (Fig. 3A). Similar results were obtained with excised patches (Fig. 3B). In both sets of recordings, GΩ seals were obtained in about 50% of attempts. The frequency with which channels were detected varied between 20 and 80% in different cell preparations. It is difficult to estimate reliably the average number of channels in a patch: too many large-conductance channels may prevent formation of a GΩ seal, and patches with undetected channels will include those that failed to respond for a variety of experimental reasons. However, most active patches included one or two active channels, and very few had 3–4 channels: the average number of channels per excised patch was 1.8 ± 0.2. An analysis that assumes a random distribution of channels between patches likewise suggests the presence of 2 channels/patch (supplemental Table S4). Assuming that our patch-clamp recordings are from 20% of the total PM, these results suggest the presence of fewer than 10 of these channels in the PM of each RINm5F cell. It proved impossible to achieve reliable whole cell recordings.

In symmetrical cesium methanesulfonate, the single channel slope conductance (γ) measured in cell-attached patches was the same whether they were stimulated with caffeine (γ = 147.7 ± 4.5 pS, n = 6) or 4CmC (γ = 148.3 ± 4.2 pS, n = 9) (Fig. 3C). We conclude that caffeine and 4CmC stimulate the same ryanodine-sensitive large-conductance cation channels in the PM of RINm5F cells.

Under similar recording conditions (symmetrical cesium methanesulphonate), 4CmC (1 mM) also activated channels in the PM of freshly isolated rat pancreatic β-cells (Fig. 3D). The slope conductance of the major conductance of these channels
Properties of Ryanodine-activated Channels in the Plasma Membrane—In excised inside-out patches, a low concentration of ryanodine (4 nM) activated channels that were unaffected by nifedipine (10 μM, not shown) or clotrimazole (Fig. 4A); the latter at a concentration (50 μM) sufficient to inhibit KATP and Ca2+-activated K+ channels (51, 52). The major conductance of the ryanodine-activated channels (γCs = 147.8 ± 3.7 pS, n = 7) was the same as that of the channels activated by caffeine and 4CmC (Fig. 4B). The current-amplitude histograms consistently suggested the presence of minor sub-conductance states with amplitudes of ~30–50% that of the main conductance (Fig. 4C). Such subconductance states are common features of RyR activated by ryanodine (53). From patches with a single channel, the maximal open probability (Po = 0.2–0.3) was similar for caffeine (1 mM), 4CmC (1 mM) and ryanodine (4 nM) (Fig. 4D), although the mean channel open time (τo) was significantly longer for ryanodine (Fig. 4E). The latter is consistent with the established ability of low concentrations of ryanodine to cause long-lasting openings of RyR (50).

Ruthenium red is an antagonist of RyR, but it is membrane-impermeant. By first activating channels with 4CmC in the cell-attached configuration and then excising the patch into BS containing ruthenium red (10 μM, upper), we demonstrated that cytosolic ruthenium red rapidly inhibits channel activity. Po in the cell-attached configuration was 0.25 ± 0.02 (n = 20), and remained at 0.24 ± 0.04 after excision into normal BS, but fell within a few seconds to 0.005 ± 0.01 after excision into BS containing ruthenium red (Fig. 5A). These results provide substantial further evidence that the 4CmC-activated cation channels in the PM have the properties expected of RyR.
Plasma Membrane Ryanodine Receptors

In excised patches stimulated with 4CmC (1 mM) under symmetrical ionic conditions, the channels were permeable not only to Cs⁺ (γCs = 148.3 ± 4.2 pS, n = 9), but also to K⁺ (γK = 169.0 ± 4.8 pS, n = 5) and Na⁺ (γNa = 130.2 ± 2.1 pS, n = 4) (Fig. 5, B and C). A similar number of channels and with similar P₀ was detected under each of these conditions (not shown). The channels were impermeable to N-methyl-D-glucamine (NMDG) chloride (Fig. 5B). Our attempts to measure Ba²⁺ and Ca²⁺ conductances were frustrated by resealing of membrane around the patch-pipette. We were, therefore, unable to determine the relative permeability of the PM channels for monovalent and bivalent cations. Comparison of γ for the PM channels with analyses of RyR2 reconstituted into lipid bilayers (54, 55) shows that after correction for the different ionic conditions, γ of the PM channels is consistently 3–4 fold lower than for RyR2 in bilayers (supplemental Table S5). Our previous analysis of IP₃R expressed in the PM or nuclear envelope also suggested that exactly the same channel can have very different γ when expressed in different membranes (56). We have no definitive explanation for these disparities, but for IP₃R we suggested that different membranes may selectively stabilize different sub-conductance states (56). A similar explanation may account for the different γ of RyR2 in the PM and bilayers.

We have shown that RyR2 are expressed in RINm5F cells (Fig. 2A) and that their distribution is consistent with a presence in the PM (Fig. 2, B and C). A variety of agonists of RyR (caffeine, 4CmC, ryanodine) activate both Ca²⁺ entry in intact cells and poorly selective large-conductance cation channels in the PM. The responses are blocked by antagonists of RyR (ryanodine, ruthenium red), but not by antagonists of other cation channels. Our final experiments use RNAi to confirm that RyR2 directly mediate these responses.

Inhibition of RyR2 Expression Inhibits Responses—Using RNAi, we selectively reduced expression of RyR1, RyR2 or IP₃R by >50%, without reducing expression of the non-targeted proteins (Fig. 6, A and B, and supplemental Table S6).

In excised patch-clamp recordings from mock-transfected cells or cells transfected with RNAi to RyR1, 4CmC-activated cation channels were detected in ~70% of recordings that achieved a GΩ seal, but the success rate fell to 21 ± 6% for cells treated with RNAi to RyR2 (Fig. 6, C and D). The peak Ca²⁺ signals evoked by 4CmC, which depend largely on Ca²⁺ entry (Fig. 1D), were also selectively attenuated by treatment with RNAi to RyR2 (Fig. 6, F and G). Likewise, the effect of 4CmC on Mn²⁺ entry was almost abolished in cells treated with RNAi to RyR2, whereas RNAi to IP₃R had no effect (Fig. 6E). We conclude that RyR2 are expressed in the PM and directly mediate Ca²⁺ entry.

Expression of Functional RyR2 in the Plasma Membrane of RINm5F Cells—We have demonstrated the expression of small numbers (~10 channels/cell) of functional RyR2 in the PM of RINm5F cells and provided more limited evidence for functional RyR in the PM of rat pancreatic β-cells. Although RyR and IP₃R are widely expressed intracellular Ca²⁺ channels, accumulating evidence suggests that the same channels may also be expressed within the PM of some cells. In B-lympho-

FIGURE 6. Activation of plasma membrane cation channels and cytosolic Ca²⁺ signals requires RyR2.

A. Western blots showing expression of RyR2, IP₃R, and calnexin in RINm5F cells after transfection with RNAi for RyR1, RyR2, or IP₃R, or after mock transfection (control). The antibody to RyR1 cannot reliably detect changes in expression of endogenous RyR1, which is expressed at 169.0 ± 4.8 pS (n = 5) and Na⁺ (γNa = 130.2 ± 2.1 pS, n = 4) (Fig. 5, B and C). A similar number of channels and with similar P₀ was detected under each of these conditions (not shown). The channels were impermeable to N-methyl-D-glucamine (NMDG) chloride (Fig. 5B). Our attempts to measure Ba²⁺ and Ca²⁺ conductances were frustrated by resealing of membrane around the patch-pipette. We were, therefore, unable to determine the relative permeability of the PM channels for monovalent and bivalent cations. Comparison of γ for the PM channels with analyses of RyR2 reconstituted into lipid bilayers (54, 55) shows that after correction for the different ionic conditions, γ of the PM channels is consistently 3–4 fold lower than for RyR2 in bilayers (supplemental Table S5). Our previous analysis of IP₃R expressed in the PM or nuclear envelope also suggested that exactly the same channel can have very different γ when expressed in different membranes (56). We have no definitive explanation for these disparities, but for IP₃R we suggested that different membranes may selectively stabilize different sub-conductance states (56). A similar explanation may account for the different γ of RyR2 in the PM and bilayers.

We have shown that RyR2 are expressed in RINm5F cells (Fig. 2A) and that their distribution is consistent with a presence in the PM (Fig. 2, B and C). A variety of agonists of RyR (caffeine, 4CmC, ryanodine) activate both Ca²⁺ entry in intact cells and poorly selective large-conductance cation channels in the PM. The responses are blocked by antagonists of RyR (ryanodine, ruthenium red), but not by antagonists of other cation channels. Our final experiments use RNAi to confirm that RyR2 directly mediate these responses.

Inhibition of RyR2 Expression Inhibits Responses—Using RNAi, we selectively reduced expression of RyR1, RyR2 or IP₃R by >50%, without reducing expression of the non-targeted proteins (Fig. 6, A and B, and supplemental Table S6).

In excised patch-clamp recordings from mock-transfected cells or cells transfected with RNAi to RyR1, 4CmC-activated cation channels were detected in ~70% of recordings that achieved a GΩ seal, but the success rate fell to 21 ± 6% for cells treated with RNAi to RyR2 (Fig. 6, C and D). The peak Ca²⁺ signals evoked by 4CmC, which depend largely on Ca²⁺ entry (Fig. 1D), were also selectively attenuated by treatment with RNAi to RyR2 (Fig. 6, F and G). Likewise, the effect of 4CmC on Mn²⁺ entry was almost abolished in cells treated with RNAi to RyR2, whereas RNAi to IP₃R had no effect (Fig. 6E). We conclude that RyR2 are expressed in the PM and directly mediate Ca²⁺ entry.

Expression of Functional RyR2 in the Plasma Membrane of RINm5F Cells—We have demonstrated the expression of small numbers (~10 channels/cell) of functional RyR2 in the PM of RINm5F cells and provided more limited evidence for functional RyR in the PM of rat pancreatic β-cells. Although RyR and IP₃R are widely expressed intracellular Ca²⁺ channels, accumulating evidence suggests that the same channels may also be expressed within the PM of some cells. In B-lympho-
cytes, for example, very small numbers of functional IP$_3$R (2–3 IP$_3$R/cell) are reliably expressed in the PM, where they mediate about half the Ca$^{2+}$ entry evoked by activation of the B-cell receptor (56, 57). IP$_3$R, possibly distinct from those in the ER, are also expressed in the PM of olfactory neurones (58) and ciliated epithelium (59).

Several studies have detected cation channels with large, although rather variable, conductances that are activated by agonists of RyR in the PM of different cell types. These include osteoblasts, where RyR2 are proposed to mediate extracellular Ca$^{2+}$-sensing (60); cardiac myocytes (61) and smooth muscle (62, 63). In each case, the density of the PM channels was very low, typically no more than ~10 channels/cell, and often just 2–3 channels/cell. None of these reports established the molecular identity of the channel and several were reluctant to conclude that it was a RyR (20, 61–63), but together they provide evidence that small numbers of RyR may be expressed in the PM of several different electrically excitable cells. Our results extend these observations to RINm5F cells and pancreatic β-cells and, more importantly, they unequivocally establish that RyR2 expressed in the PM can directly mediate Ca$^{2+}$ entry.

These results indicate that in some cells, small numbers of IP$_3$R or RyR can be expressed in the PM and mediate Ca$^{2+}$ entry. The small number of these channels is significant because both RyR and IP$_3$R have such large conductances (Figs. 3C, 4B, and 5C) that very few channels can mediate substantial Ca$^{2+}$ entry (56).

RyR are implicated in the responses of pancreatic β-cells to glucose and incretins (see Introduction); many diabetic states are associated with a loss of RyR from β-cells (10); and the immunosuppressant, FK-506, which interacts with RyR via FKBP (64), is a major cause of post-transplantation diabetes mellitus (65). But the specific roles of RyR in β-cells are incompletely resolved (7, 10, 66). It is, however, clear that whereas both IP$_3$R and RyR are expressed in the ER of insulinoma cells, only RyR are expressed in secretory vesicles (8) or endosomes (10). Selective targeting of RyR (and not IP$_3$R) to the secretory vesicles of β-cells might therefore be one step that contributes to selective expression of small numbers of RyR in the PM.

Abundant evidence implicates RyR in mediating physiological responses of β-cells to glucose and incretins (see Introduction). Our results suggest that their involvement in these responses is likely to involve RyR within both intracellular stores and the PM, and within the latter it is likely that RyR may directly mediate Ca$^{2+}$ entry and contribute to regulation of membrane potential. It remains unclear whether the non-ER RyR reside predominantly in endosomes or secretory vesicles (8, 10), but it is significant that their presence in either organelle suggests a dynamic relationship between exocytosis of insulin-containing vesicles and trafficking of RyR2 between intracellular organelles and the PM.

We have shown that small numbers of functional RyR2 are expressed in the PM of RINm5F insulinoma cells and rat pancreatic β-cells, where they directly mediate Ca$^{2+}$ entry and may also regulate membrane potential. We suggest that exocytosis of insulin containing vesicles and the subsequent retrieval of membrane by endocytosis (67) may allow dynamic regulation of RyR expression in the PM.

**Acknowledgments**—We thank G. Meissner for providing the antisera for RyR1, and N. Smith and S. Ozanne for help with β-cells.

**REFERENCES**

1. Foskett, J. K., White, C., Cheung, K. H., and Mak, D. O. (2007) Physiol. Rev. 87, 593–658
2. Hamilton, S. L. (2005) Cell Calcium 38, 253–260
3. Taylor, C. W., Genazzani, A. A., and Morris, S. A. (1999) Cell Calcium 26, 237–251
4. Sutko, J. L., and Airey, J. A. (1996) Physiol. Rev. 76, 1027–1071
5. Blondel, O., Takeda, J., Janssen, H., Seino, S., and Bell, G. I. (1993) J. Biol. Chem. 268, 11356–11363
6. Swatton, J. E., Morris, S. A., Cardy, T. J. A., and Taylor, C. W. (1999) Biochem. J. 344, 55–60
7. Islam, M. S. (2002) Diabetes 51, 1299–1309
8. Mitchell, K. J., Pinton, P., Varadi, A., Tacchetti, C., Ainscow, E. K., Pozzan, T., Rizzuto, R., and Rutter, G. A. (2001) J. Cell Biol. 155, 41–51
9. Mitchell, K. J., Lai, F. A., and Rutter, G. A. (2003) J. Biol. Chem. 278, 11057–11064
10. Johnson, J. D., Kuang, S., Misler, S., and Polonsky, K. S. (2004) FASEB J. 18, 878–880
11. Blondel, O., Bell, G. I., Moody, M., Miller, R. J., and Gibbons, S. I. (1994) J. Biol. Chem. 269, 27167–27170
12. Ravazzola, M., Halban, P. A., and Orci, L. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 2745–2748
13. Prentki, M., Biden, T. J., Janjic, D., Irvine, R. F., Berridge, M. J., and Wollheim, C. B. (1984) Nature 309, 562–564
14. Takasawa, S., Akiyama, T., Naka, K., Kuroki, M., Tohgo, A., Noguchi, N., Kobayashi, S., Kato, I., Katada, T., and Okamoto, H. (1998) J. Biol. Chem. 273, 2497–2500
15. Patterson, R. L., Boehning, D., and Snyder, S. H. (2004) Annu. Rev. Biochem. 73, 437–465
16. Bers, D. M. (2004) J. Mol. Cell. Cardiol. 37, 417–429
17. Williams, A. J. (2002) Front. Biosci. 7, 1–8
18. Gillespie, D., and Fill, M. (2008) Biophys. J. 95, 3706–3714
19. Nichols, C. G. (2006) Nature 440, 470–476
20. Gustafsson, A. J., Ingelman-Sundberg, H., Dzabic, M., Awasum, J., Nguyen, K. H., Ostenson, C. G., Pierro, C., Tedeschi, P. W., Woolcott, O., Chiouan, S., Lund, P. E., Larsson, O., and Islam, M. S. (2005) FASEB J. 19, 301–303
21. Ashcroft, F. M., Proks, P., Smith, P. A., Ammala, C., Bokvist, K., and Rorsman, P. (1994) J. Cell. Biochem. 55 (suppl.), 54–65
22. Bokvist, K., Eliasson, L., Ammala, C., Renstrom, E., and Rorsman, P. (1995) EMBO J. 14, 50–57
23. Wiederkehr, A., and Wollheim, C. B. (2006) Endocrinology 147, 2643–2649
24. Rojas, E., Carroll, P. B., Ricordi, C., Boschero, A. C., Stojilkovic, S. S., and Atwater, I. (1994) Endocrinology 134, 1771–1781
25. Henquin, J. C. (2000) Diabetes 49, 1751–1760
26. Shigeto, M., Katsura, M., Matsuura, M., Ohkuma, S., and Kaku, K. (2007) J. Pharmacol. Exp. Ther. 322, 1–7
27. Dyachok, O., and Gyfle, E. (2004) J. Biol. Chem. 279, 45455–45461
28. Kermode, H., Williams, A. J., and Sitesapesan, R. (1998) Biophys. J. 74, 1296–1304
29. Drucker, D. J. (2006) Cell Metab 3, 153–165
30. Holst, J. J. (2007) Physiol. Rev. 87, 1409–1439
31. Holz, G. G. (2004) Diabetes 53, 5–13
32. Szaszak, M., Christian, F., Rosenthal, W., and Klussmann, E. (2007) Cell. Signal. 20, 590–601
33. Holz, G. G., Leech, C. A., Heller, R. S., Castonguay, M., and Habener, J. F. (1999) J. Biol. Chem. 274, 14147–14156
34. Tsuboi, T., da Silva Xavier, G., Holz, G. G., Jouaville, L. S., Thomas, A. P., and Rutter, G. A. (2003) Biochem. J. 369, 287–299
35. Kang, G., Chepurny, O. G., and Holz, G. G. (2001) J. Physiol. 536, 375–385
36. Gromada, J., Dissing, S., Bokvist, K., Renstrom, E., Franek-Jensen, J., Wulff, B. S., and Rorsman, P. (1995) Diabetes 44, 767–774

FEBRUARY 20, 2009 • VOLUME 284 • NUMBER 8
Plasma Membrane Ryanodine Receptors

37. Dyachok, O., Isakov, Y., Sagetorp, J., and Tengholm, A. (2006) *Nature* **439**, 349–352
38. Lacy, P. E., and Kostianovsky, M. (1967) *Diabetes* **16**, 35–39
39. Meissner, G., Rousseau, E., and Lai, F. A. (1989) *J. Biol. Chem.* **264**, 1715–1722
40. Warton, K., Foster, N. C., Gold, W. A., and Stanley, K. K. (2004) *Gene* **342**, 85–95
41. Fessenden, J. D., Perez, C. F., Goth, S., Pessah, I. N., and Allen, P. D. (2003) *J. Biol. Chem.* **278**, 28727–28735
42. Woolcott, O. O., Gustafsson, A. J., Dzabic, M., Pierro, C., Tedeschi, P., Sandgren, J., Bari, M. R., Nguyen, K. H., Bianchi, M., Rakonjac, M., Radmark, O., Ostenson, C. G., and Islam, M. S. (2006) *Cell Calcium* **39**, 529–537
43. Parekh, A. B., and Putney, J. W. (2005) *Physiol. Rev.* **85**, 757–810
44. Yamasaki, M., Masgrau, R., Morgan, A. J., Churchill, G. C., Patel, S., Ashcroft, S. J., and Galione, A. (2004) *J. Biol. Chem.* **279**, 7234–7240
45. Liu, Y. J., and Gylfe, E. (1997) *Cell Calcium* **22**, 277–286
46. Miura, Y., Henquin, J. C., and Gilon, P. (1997) *J. Physiol.* **503**, 387–398
47. Mears, D., Leighton, X., Atwater, L., and Rojas, E. (1999) *Cell Calcium* **25**, 59–68
48. Lee, B., Bradford, P. G., and Laychock, S. G. (1998) *J. Mol. Endocrinol.* **21**, 31–39
49. Johnson, J. D., Han, Z., Otani, K., Ye, H., Zhang, Y., Wu, H., Horikawa, Y., Misler, S., Bell, G. I., and Polonsky, K. S. (2004) *J. Biol. Chem.* **279**, 24794–24802
50. Santonastasi, M., and Wehrens, X. H. (2007) *Acta Pharma. Sin.* **28**, 937–944
51. Tian, M., Dong, M. Q., Chiu, S. W., Lau, C. P., and Li, G. R. (2006) *Br. J. Pharmacol.* **147**, 289–297
52. Welker, S., and Drews, G. (1997) *Naunyn-Schmiedeberg's Arch. Pharmacol.* **356**, 543–550
53. Fill, M., and Copello, J. A. (2002) *Physiol. Rev.* **82**, 893–922
54. Lindsay, A. R. G., Manning, S. D., and Williams, A. J. (1991) *J. Physiol.* **439**, 463–480
55. Williams, A. J., West, D. J., and Sitespesan, R. (2001) *Quart. Rev. Biophys.* **34**, 61–104
56. Dellis, O., Dedos, S., Tovey, S. C., Rahman, T.-U., Dubel, S. J., and Taylor, C. W. (2006) *Science* **313**, 229–233
57. Dellis, O., Rossi, A. M., Dedos, S. G., and Taylor, C. W. (2008) *J. Biol. Chem.* **283**, 751–755
58. Fadool, D. A., and Ache, B. W. (1992) *Neuron* **9**, 907–918
59. Barrera, N. P., Morales, B., and Villalon, M. (2007) *Biochem. Biophys. Res. Commun.* **364**, 815–821
60. Huang, C. L., Sun, L., Fraser, I. A., Grace, A. A., and Zaidi, M. (2007) *Ann. N. Y. Acad. Sci.* **1116**, 255–270
61. Zhang, Y. A., Tuft, R. A., Lifshitz, L. M., Fogarty, K. E., Singer, J. I., and Zou, H. (2007) *Am. J. Physiol.* **293**, H2448–H2461
62. Guerrero, A., Fay, F. S., and Singer, J. I. (1994) *J. Gen. Physiol.* **104**, 375–394
63. Loirand, G., Pacaud, P., Baron, A., Mironneau, C., and Mironneau, J. (1991) *J. Physiol.* **437**, 461–475
64. Samso, M., Shen, X., and Allen, P. D. (2006) *J. Mol. Biol.* **356**, 917–927
65. Penfornis, A., and Kury-Paulin, S. (2006) *Diabetes Metab.* **32**, 539–546
66. Zhan, X., Yang, X., and Jia, Y. (2008) *Eur. J. Biophys.* **37**, 773–782
67. MacDonald, P. E., and Rorsman, P. (2007) *Physiology (Bethesda)* **22**, 113–121